| Literature DB >> 34239696 |
Md Sahab Uddin1,2, Abdullah Al Mamun3, Md Motiar Rahman4, Philippe Jeandet5, Athanasios Alexiou6,7, Tapan Behl8, Md Shahid Sarwar9, Eduardo Sobarzo-Sánchez10,11, Ghulam Md Ashraf12,13, Amany A Sayed14, Ghadeer M Albadrani15, Ilaria Peluso16, Mohamed M Abdel-Daim17.
Abstract
Neurodegenerative disorders (NDs) are heterogeneous groups of ailments typically characterized by progressive damage of the nervous system. Several drugs are used to treat NDs but they have only symptomatic benefits with various side effects. Numerous researches have been performed to prove the advantages of phytochemicals for the treatment of NDs. Furthermore, phytochemicals such as polyphenols might play a pivotal role in rescue from neurodegeneration due to their various effects as anti-inflammatory, antioxidative, and antiamyloidogenic agents by controlling apoptotic factors, neurotrophic factors (NTFs), free radical scavenging system, and mitochondrial stress. On the other hand, neurotrophins (NTs) including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), NT4/5, and NT3 might have a crucial neuroprotective role, and their diminution triggers the development of the NDs. Polyphenols can interfere directly with intracellular signaling molecules to alter brain activity. Several natural products also improve the biosynthesis of endogenous genes encoding antiapoptotic Bcl-2 as well as NTFs such as glial cell and brain-derived NTFs. Various epidemiological studies have demonstrated that the initiation of these genes could play an essential role in the neuroprotective function of dietary compounds. Hence, targeting NTs might represent a promising approach for the management of NDs. In this review, we focus on the natural product-mediated neurotrophic signal-modulating cascades, which are involved in the neuroprotective effects.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34239696 PMCID: PMC8241508 DOI: 10.1155/2021/8820406
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Role of phytochemicals involved in neuroprotection against neurodegeneration. Phytochemicals or neurotrophins bind to Trk receptor that subsequently activates PL-Cγ, Ras/MAPK, and PI3K/AKT pathways. Then, these signaling cascades trigger CREB that ultimately plays a pivotal role in protecting neurons to combat neurodegeneration. Furthermore, phytochemicals or neurotrophins also attach with NGF-p75NTR receptor and activate bidirectional cell survival and apoptosis through NF-κB and JNK signaling pathways.
Figure 2Phytochemicals activate the Keap-Nrf2-antioxidant response element cascade to increase the expression of antioxidant enzymes that fight against neurodegeneration.
Figure 3Chemical structures of the several phytochemicals that modulate the neurotrophic signals to attenuate neurodegeneration.
Promising studies regarding neurotrophic signals modulating potential of phytochemicals against neurodegeneration.
| Phytochemicals | Species/studied material | Experimental model | Dose | Therapeutic uses | Mechanisms | Induced Neurotrophins | References |
|---|---|---|---|---|---|---|---|
| Epigallocatechin-3-gallate | C57BL/6 mice | Sevoflurane-induced neurotoxicity | 25, 50, or 75 mg/kg | Neuroprotection | Activates CREB/BDNF/TrkB and PI3K/Akt/mTOR signalling pathway | BDNF | [ |
| Rats | Acrylamide-induced neurotoxicity | 10 mg/kg | Neuroprotection | Enhances acetylcholinesterase activity and reduces the expression of iNOS and COX-2 level | BDNF | [ | |
| Sprague–Dawley rats | Spinal cord injury | 10 and 20 mg/kg | Neuroprotection | Upregulation of BDNF and GDNF | BDNF, GDNF | [ | |
| PC12 cells | Oxidative-radical-stress-induced apoptosis | 0, 50, 100, 150 or, 200 | Neurodegenerative disorders | Activates PI3K/Akt and inhibits GSK-3 | NGF | [ | |
| Curcumin | Rats | Stress-induced damage to hippocampal neurons | 5, 10, and 20 mg/kg | Enhances hippocampal neurogenesis | Upregulation of 5-HT(1A) receptors and BDNF | BDNF | [ |
| Male Sprague–Dawley (SD) rats | 6-OHDA-induced Parkinson's disease | 5, 10, and 20 mg/kg | Neural regeneration and neuroprotection | Activates Trk/PI3K signaling pathways | BDNF | [ | |
| C57BL mice | MPTP-induced mice | 0.5% or 2.0% (w/w) | Neuroprotective effect | Increases expression of GDNF and TGF | GDNF | [ | |
| Rats | A | 50 and 2.5 mg/kg | Improves cognitive deficit and neuroprotection | Activates PI3K/Akt signaling pathways and inhibits GSK-3 | BDNF | [ | |
| Adult and aged mice | D-galactose-induced | 300 mg/kg | Improves cognitive impairment | Activates CREB signaling in the hippocampal dentate gyrus | BDNF | [ | |
| Rodent cortical neurons | 5 and 10 | Neuroprotection | Mediates through BDNF/TrkB-MAPK/PI-3 K-CREB signaling pathway | BDNF | [ | ||
| Resveratrol | Adult Wistar rats | Two-vessel occlusion | 20 mg/kg | Neuritogenesis, neuroinflammation, and neuroprotection | Activates ERK-mediated CREB regulation, induces BDNF, NGF, and GDNF secretion, and inhibits IL10, IL-1 | BDNF and NGF | [ |
| Female Wistar rats | Dopaminergic neurons | 25–100 | Produces neurotrophic effects | Promotes the release of neurotrophic factors | BDNF and GDNF | [ | |
| Female Wistar rats | Astroglia-enriched cultures | 25-100 | Neurological diseases | Induces the phosphorylation of (ERK1/2) andCREB in astroglia | BDNF and GDNF | [ | |
| Male Wistar rats | Chronic unpredictable mild stress-induced behavioral abnormalities | 20, 40 and 80 mg/kg | Antidepressant-like effects | Upregulates pERK, pCREB, and BDNF levels in the hippocampus and amygdala | BDNF | [ | |
| Male Wistar rats | Phenylephrine-induced contraction of vascular smooth muscle cells | 10 mg/kg | Neuroprotection | Increases BDNF serum concentrations and reduces the contractility of resistance arteries via NOS-3-independent mechanisms | BDNF | [ | |
| Quercetin | Male Chinese | High-fat diet | 8.5 and 17 mg/kg | Improves cognitive impairment | Modulates PI3K/AKT/Nrf2 pathway and activates CREB pathway | BDNF | [ |
| Adult male Sprague Dawley rat | Hypobaric hypoxia-induced memory deficit | 50, 75 or 100 mg/kg | Ameliorates cognitive impairment | Regulates the expression of sirtuin 1, PGC-1 | BDNF | [ | |
| Male Wistar albino rats | Streptozotocin-induced diabetes model | 50 mg/kg | Neuroprotection | Akt survival pathway, enhances the level of TrkB and Bcl-2, and reduces the level of both cytochrome c and caspase-3 | BDNF and NGF | [ | |
| Adult male albino rats | Polychlorinated biphenyls-induced neurotoxicity | 50 mg/kg | Protects and prevents neuronal damage | Prevents transmembrane tight junctional proteins and cytoplasmic accessory tight junctional proteins in the hippocampus and keeps the level of estradiol | BDNF | [ | |
| Daidzein | H19-7/IGF-IR neural cell line | 20 nM -2000 nM | Neuroprotection | Blocks a selective Trk receptors inhibitor, K252a | BDNF | [ | |
| Alpinetin, luteolin, calycosin, isohamnerin | Primary rat astrocytes | 10 | Improves neurodegenerative diseases | Triggers estrogen signaling | BDNF, GDNF and NGF | [ | |
| Ginkgolide B | Cultured hippocampal neurons | A | 40 | Neuroprotection | Upregulates BDNF | BDNF | [ |
| Naringin | Sprague-Dawley rats | Spinal cord injury | 20 and 40 mg/kg | Neuroprotection | Upregulates BDNF and VEGF and the inhibits the neural apoptosis | BDNF and VEGF | [ |
| Genistein | Primary rat astrocytes | 10 | Improves neurodegenerative diseases | Triggers estrogen signaling | BDNF, GDNF and NGF | [ | |
| H19-7/IGF-IR neural cell line | 20 nM -2000 nM | Neuroprotection | Blocks a selective Trk receptors inhibitor, K252a | BDNF | [ | ||
| Butein, fisetin | Mice | Glutamate-induced neurotoxicity | 40 mg/kg | Enhances cognitive effects | Inhibits iNOS and COX-2 and reactivates CREB-BDNF pathway | BDNF | [ |
| Apigenin | Mice | MPTP-induced Parkinson's disease mice | 5, 10 and 20 mg/kg | Treatment of Parkinson's disease | Reduces oxidative damage, neuroinflammation, and microglial activation | BDNF | [ |
| Epicatechin | Male C57BL/6 J mice | Hippocampus of anxiety mice | 4 mg/day | Treatment of mood disorders | Modulates monoaminergic and neurotrophic systems | BDNF | [ |
| Rosmarinic acid | Sprague-Dawley rats | Chronic unpredictable stress | 10 mg/kg | Improves depressive-like behaviors | Alters in ERK1/2 signaling | BDNF | [ |
| Baicalein | Mice | Chronic unpredictable mild stress | 1, 2, and 4 mg/kg | Treatment of depression | Triggers ERK-mediated neurotrophic action | BDNF | [ |
| Ferulic acid | Mice | Corticosterone-induced | 50, 100, or 250 mg/kg | Treatment of mood disorders | Increases CREB phosphorylation and BDNF mRNA level in the hippocampus | BDNF | [ |